Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Refractory/Relapsed Lymphoid Malignancies

NCT02846935 is registered in ClinicalTrials.gov with Yogen Saunthararajah as lead sponsor.

NCT NCT02846935
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02846935 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Refractory/Relapsed Lymphoid Malignancies
Lead sponsor
Yogen Saunthararajah
Phase
Phase 1
Overall status
Completed
Start date
April 25, 2017
Completion date
January 22, 2018
Enrollment
7 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

aggressive b-cell lymphoma, indolent b-cell lymphoma, non-hodgkin's lymphomas, t-cell lymphoma